• 1. An integrated chip for immunofluorescence and its application to analyze lysosomal storage disorders
  Jie Shen,Ying Zhou,Tu Lu,Junya Peng,Zhixiang Lin,Yuhong Pang,Li Yu Lab Chip, 2012,12, 317-324
• 2. Achieving crystal-induced room temperature phosphorescence and reversible photochromic properties by strong intermolecular interactions?
  Fuming Xiao,Mengzhu Wang,Yunxiang Lei,Wenbo Dai,Yunbing Zhou,Miaochang Liu,Wenxia Gao,Xiaobo Huang,Huayue Wu J. Mater. Chem. C, 2020,8, 17410-17416
• 3. An amorphous carbon nitride/NiO/CoN-based composite: a highly efficient nonprecious electrode for supercapacitors and the oxygen evolution reaction?
  Huifang Yang,Haoran Guo,Peidong Fan,Xinpan Li,Wenlu Ren,Rui Song Nanoscale, 2020,12, 7024-7034
• 4. An assay for the enzyme N-acetyl-β-d-glucosaminidase (NAGase) based on electrochemical detection using screen-printed carbon electrodes (SPCEs)
  R. M. Pemberton,J. P. Hart,T. T. Mottram Analyst, 2001,126, 1866-1871
• 5. An atomistic mechanism for the degradation of perovskite solar cells by trapped charge?
  Eunhak Lim,Jiyoung Heo,Seong Keun Kim Nanoscale, 2019,11, 11369-11378

Introduction to 4-(2-methyloxolan-3-yl)aminobutan-2-ol (CAS No: 1543475-64-4)

4-(2-methyloxolan-3-yl)aminobutan-2-ol, identified by the Chemical Abstracts Service Number (CAS No) 1543475-64-4, is a compound of significant interest in the field of pharmaceutical chemistry and medicinal biology. This molecule, featuring a unique structural framework that combines an amino group, a hydroxyl group, and an oxygen-containing heterocycle, has garnered attention for its potential applications in drug discovery and molecular research. The presence of a methylene oxide (lactol) moiety appended to an amine-substituted butanediol backbone suggests versatile reactivity, making it a valuable scaffold for further chemical derivatization and biological evaluation.

The structural motif of 4-(2-methyloxolan-3-yl)aminobutan-2-ol positions it as a candidate for exploring novel pharmacophores. The lactol ring, characterized by its puckered conformation and partial double-bond character, can influence the compound's solubility, metabolic stability, and interaction with biological targets. The amine functionality provides a site for hydrogen bonding and potential covalent or non-covalent interactions with proteins or nucleic acids. Meanwhile, the hydroxyl groups contribute to hydrogen bonding capacity and may modulate the compound's pharmacokinetic properties.

In recent years, the development of small molecules with complex scaffolds has been instrumental in addressing unmet medical needs. Compounds like 4-(2-methyloxolan-3-yl)aminobutan-2-ol represent an emerging class of molecules that bridge synthetic accessibility with structural complexity. The lactol group, in particular, has been explored in various therapeutic contexts due to its ability to form stable cyclic derivatives or participate in dynamic equilibrium processes. This structural feature makes it an attractive component for designing molecules with enhanced binding affinity or selectivity.

From a synthetic chemistry perspective, 4-(2-methyloxolan-3-yl)aminobutan-2-ol can serve as a versatile intermediate for constructing more elaborate molecular architectures. The amine and hydroxyl groups offer multiple points for functionalization via reductive amination, etherification, or other coupling reactions. This adaptability allows chemists to tailor the compound's properties for specific applications, such as prodrug design or the development of enzyme inhibitors. The lactol ring itself can be modified by oxidation to afford diols or reduced to form alcohols, further expanding its synthetic utility.

The biological relevance of 4-(2-methyloxolan-3-yl)aminobutan-2-ol is underscored by its potential interactions with biological systems. Preliminary studies have suggested that similar scaffolds may exhibit activity against enzymes involved in metabolic pathways or signal transduction cascades. The oxygen-containing heterocycle often plays a critical role in modulating binding affinity through dipole interactions or hydrogen bonding networks. Furthermore, the presence of multiple stereocenters (if applicable) could contribute to enantioselective pharmacology, where chirality significantly influences biological activity.

In light of current research trends, 4-(2-methyloxolan-3-yl)aminobutan-2-ol aligns with the growing interest in "privileged scaffolds"—molecular motifs known for their recurrent occurrence in bioactive natural products and drug candidates. These scaffolds are often favored due to their perceived druggability and favorable physicochemical properties. The combination of features found in this compound—such as the lactol ring and dual amine/hydroxyl functionality—positions it as a promising candidate for further exploration within this framework.

Recent advancements in computational chemistry have enabled the rapid screening of such compounds for potential biological activity. Virtual screening techniques can be employed to identify how 4-(2-methyloxolan-3-yl)aminobutan-2-ol might interact with target proteins or enzymes based on its 3D structure. This approach allows researchers to prioritize molecules for experimental validation while minimizing resource expenditure on less promising candidates. Such high-throughput virtual screening pipelines are becoming increasingly integral to modern drug discovery programs.

The pharmacokinetic profile of 4-(2-methyloxolan-3-yl)aminobutan-2-ol is another critical consideration in its development as a therapeutic agent. Factors such as solubility, permeability across biological membranes (P-glycoprotein substrate status), and metabolic stability must be carefully evaluated. The lactol ring may influence these properties by affecting polarity or susceptibility to enzymatic degradation. Advanced physicochemical modeling tools can predict these characteristics before experimental synthesis begins, streamlining the optimization process.

From an industrial standpoint, the scalability of synthesizing 4-(2-methyloxolan-3-y1)aminobutan - 2 - ol is an important practical consideration. Efficient synthetic routes must be developed to ensure cost-effective production at kilogram quantities if clinical development proceeds successfully. Process chemists focus on optimizing reaction conditions—such as catalyst selection or solvent systems—to maximize yield while maintaining purity standards required for pharmaceutical use.

The regulatory landscape also plays a role in advancing compounds like 4-( 2 - meth y lo x o lan - 3 - y l ) ami no bu tan - 2 - o l through clinical trials . Compliance with Good Manufacturing Practices (GMP) ensures that materials used in research studies meet stringent quality control measures . Additionally , any proposed therapeutic indication must undergo rigorous evaluation through preclinical toxicology studies before human testing can commence . These steps are essential steps toward bringing safe , effective treatments from benchtops into patient care .

In conclusion, 4 - ( 2 - meth y lo x o lan - 3 - y l ) ami no bu tan - 2 - o l ( CAS No: 1543475 -64 -4 ) represents an intriguing molecular entity with potential applications across pharmaceutical research , chemical synthesis , and medicinal chemistry . Its unique structural features—particularly the interplay between its oxygen-containing heterocycle , amino , hydroxyl groups —make it worth investigating further . As methodologies evolve for drug discovery , compounds such as this one continue to serve important roles both academically , industrially , contributing toward next-generation therapies . Future work should focus on elucidating its full spectrum of reactivity , exploring novel derivatives , while assessing how best integrate into existing medicinal chemistry pipelines . By doing so scientists hope unlock new possibilities treating complex diseases challenges modern healthcare faces today . p>

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)